Gene Therapy Successfully Restores Hearing in Children
Otarmeni, a new gene therapy for OTOF-associated hearing loss, has shown promising results, with 80% of treated children experiencing improved hearing within 24 weeks after treatment.
Otarmeni, the first FDA-approved gene therapy for OTOF-associated hearing loss, has made significant strides in restoring hearing for children born with this rare form of deafness. In a recent clinical trial involving 24 participants aged 10 months to 16 years, about 80% of those treated experienced improved hearing within 24 weeks of receiving the therapy. Additionally, 42% of these children regained functional hearing, highlighting the potential of gene therapy to address congenital hearing loss. This development marks a pivotal moment in the field of audiology, especially for individuals affected by mutations in the otoferlin gene (OTOF), which plays a crucial role in sound signal transmission in the inner ear.
Enjoyed this story?
Show the newsroom a little love — one tap per reader.
Priya reports on breakthroughs that change lives, big and small.
Be part of the good
Stories like this start with people who care. Share it, or submit your own uplifting story to inspire millions today.
